schliessen

Filtern

 

Bibliotheken

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum

The trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features to develop individualized therapy regimens. In June... Full description

Journal Title: Diabetes care September 2014, Vol.37(9), pp.2647-59
Main Author: Cefalu, William T
Other Authors: Buse, John B , Del Prato, Stefano , Home, Philip D , Leroith, Derek , Nauck, Michael A , Raz, Itamar , Rosenstock, Julio , Riddle, Matthew C
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1935-5548 ; PMID: 25147257 Version:1 ; DOI: 10.2337/dc14-1395
Link: http://pubmed.gov/25147257
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline25147257
title: Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
format: Article
creator:
  • Cefalu, William T
  • Buse, John B
  • Del Prato, Stefano
  • Home, Philip D
  • Leroith, Derek
  • Nauck, Michael A
  • Raz, Itamar
  • Rosenstock, Julio
  • Riddle, Matthew C
subjects:
  • Patient-Centered Care
  • Diabetes Mellitus, Type 2 -- Drug Therapy
  • Hypoglycemic Agents -- Therapeutic Use
  • Metformin -- Therapeutic Use
ispartof: Diabetes care, September 2014, Vol.37(9), pp.2647-59
description: The trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features to develop individualized therapy regimens. In June 2013, a nine-member Diabetes Care Editors' Expert Forum convened to review safety evidence for six major diabetes drug classes: insulin, sulfonylureas (SUs), thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium glucose cotransporter 2 inhibitors. This article, an outgrowth of the forum, summarizes well-delineated and theoretical safety concerns related to these drug classes, as well as the panelists' opinions regarding their best use in patients with type 2 diabetes. All of the options appear to have reasonably wide safety margins when used appropriately. Those about which we know the most-metformin, SUs, insulin, and perhaps now...
language: eng
source:
identifier: E-ISSN: 1935-5548 ; PMID: 25147257 Version:1 ; DOI: 10.2337/dc14-1395
fulltext: fulltext
issn:
  • 19355548
  • 1935-5548
url: Link


@attributes
ID141634468
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid25147257
sourceidmedline
recordidTN_medline25147257
sourceformatXML
sourcesystemPC
pqid1555628802
galeid382846326
display
typearticle
titleBeyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
creatorCefalu, William T ; Buse, John B ; Del Prato, Stefano ; Home, Philip D ; Leroith, Derek ; Nauck, Michael A ; Raz, Itamar ; Rosenstock, Julio ; Riddle, Matthew C
ispartofDiabetes care, September 2014, Vol.37(9), pp.2647-59
identifier
subjectPatient-Centered Care ; Diabetes Mellitus, Type 2 -- Drug Therapy ; Hypoglycemic Agents -- Therapeutic Use ; Metformin -- Therapeutic Use
descriptionThe trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features to develop individualized therapy regimens. In June 2013, a nine-member Diabetes Care Editors' Expert Forum convened to review safety evidence for six major diabetes drug classes: insulin, sulfonylureas (SUs), thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium glucose cotransporter 2 inhibitors. This article, an outgrowth of the forum, summarizes well-delineated and theoretical safety concerns related to these drug classes, as well as the panelists' opinions regarding their best use in patients with type 2 diabetes. All of the options appear to have reasonably wide safety margins when used appropriately. Those about which we know the most-metformin, SUs, insulin, and perhaps now...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/25147257$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Cefalu, William T
1Buse, John B
2Del Prato, Stefano
3Home, Philip D
4LeRoith, Derek
5Nauck, Michael A
6Raz, Itamar
7Rosenstock, Julio
8Riddle, Matthew C
titleBeyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
descriptionThe trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features to develop individualized therapy regimens. In June 2013, a nine-member Diabetes Care Editors' Expert Forum convened to review safety evidence for six major diabetes drug classes: insulin, sulfonylureas (SUs), thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium glucose cotransporter 2 inhibitors. This article, an outgrowth of the forum, summarizes well-delineated and theoretical safety concerns related to these drug classes, as well as the panelists' opinions regarding their best use in patients with type 2 diabetes. All of the options appear to have reasonably wide safety margins when used appropriately. Those about which we know the most-metformin, SUs, insulin, and perhaps now...
subject
0Patient-Centered Care
1Diabetes Mellitus, Type 2 -- Drug Therapy
2Hypoglycemic Agents -- Therapeutic Use
3Metformin -- Therapeutic Use
general
025147257
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.2337/dc14-1395
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline25147257
issn
019355548
11935-5548
rsrctypearticle
creationdate2014
addtitleDiabetes care
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41201409
citationpf 2647 vol 37 issue 9
startdate20140901
enddate20140931
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleBeyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
authorCefalu, William T ; Buse, John B ; Del Prato, Stefano ; Home, Philip D ; Leroith, Derek ; Nauck, Michael A ; Raz, Itamar ; Rosenstock, Julio ; Riddle, Matthew C
creationdate20140900
lso0120140900
facets
frbrgroupid7558187161045595985
frbrtype5
newrecords20190701
languageeng
creationdate2014
topic
0Patient-Centered Care
1Diabetes Mellitus, Type 2–Drug Therapy
2Hypoglycemic Agents–Therapeutic Use
3Metformin–Therapeutic Use
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Cefalu, William T
1Buse, John B
2Del Prato, Stefano
3Home, Philip D
4Leroith, Derek
5Nauck, Michael A
6Raz, Itamar
7Rosenstock, Julio
8Riddle, Matthew C
jtitleDiabetes Care
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Cefalu
1Buse
2Del Prato
3Home
4Leroith
5Nauck
6Raz
7Rosenstock
8Riddle
aufirst
0William T
1John B
2Stefano
3Philip D
4Derek
5Michael A
6Itamar
7Julio
8Matthew C
au
0Cefalu, William T
1Buse, John B
2Del Prato, Stefano
3Home, Philip D
4Leroith, Derek
5Nauck, Michael A
6Raz, Itamar
7Rosenstock, Julio
8Riddle, Matthew C
atitleBeyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
jtitleDiabetes care
risdate201409
volume37
issue9
spage2647
pages2647-2659
issn0149-5992
eissn1935-5548
formatjournal
genrearticle
ristypeJOUR
abstractThe trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features to develop individualized therapy regimens. In June 2013, a nine-member Diabetes Care Editors' Expert Forum convened to review safety evidence for six major diabetes drug classes: insulin, sulfonylureas (SUs), thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium glucose cotransporter 2 inhibitors. This article, an outgrowth of the forum, summarizes well-delineated and theoretical safety concerns related to these drug classes, as well as the panelists' opinions regarding their best use in patients with type 2 diabetes. All of the options appear to have reasonably wide safety margins when used appropriately. Those about which we know the most-metformin, SUs, insulin, and perhaps now...
doi10.2337/dc14-1395
pmid25147257
date2014-09